QBiotics – equity proposition

QBiotics – equity proposition

QBiotics — 1 video in collection

More on this equity

QBiotics is a clinical-stage biotechnology company focused on the development of novel small molecule therapies derived from natural compounds. Its lead asset, tigilanol tiglate, is designed to directly target tumours following local injection, with immune-mediated effects. The company is advancing this programme across multiple solid tumour indications.

We highlight the key points of QBiotics’ investment story.

  1. A differentiated oncology asset addressing areas of unmet need.
  2. Encouraging early clinical data and strong validation signals.
  3. Clear path to near-term value inflection through partnering.
  4. Platform underpinned pipeline provides longer-term upside.

For further details, please refer to our latest research on the Edison website.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.